Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Sarcoma 1Gynecologic 1CNS 1

Conditions

Sarcoma, Endometrial Stromal 1Perivascular Epithelioid Cell Neoplasms 1Adenosarcoma of the uterus 1

Interventions

Specimen Handling 39Magnetic Resonance Spectroscopy 33Cyclophosphamide 30Doxorubicin 24Biopsy 24pembrolizumab 22Temozolomide 22Radiotherapy 20Radiation 19X-Rays 18Nivolumab 15Vincristine 13Irinotecan 13fludarabine 12Phantoms, Imaging 12Ifosfamide 12Gemcitabine 12atezolizumab 11cabozantinib 10Ipilimumab 9Bevacizumab 9liposomal doxorubicin 8Surgical Procedures, Operative 8Paclitaxel 8Immunoglobulin G 8Etoposide 8Dactinomycin 7Carboplatin 7palbociclib 6olaparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
RAD1901 × Sarcoma × 90 days × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡